Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2025 | Measures of financial toxicity during pediatric ALL treatment: report from the DFCI ALL 16-001 trial

Daniel Zheng • 7 Dec 2025
ASH 2025
Acute Lymphoblastic Leukemia Leukemia
DFCI ALL 16-001

In this press briefing, Daniel Zheng, MD, MHS, Children’s Hospital of Philadelphia, Philadelphia, PA, shares insights into the cumulative incidence of household material hardship and income loss as measures of financial toxicity during pediatric acute lymphoblastic leukemia (ALL) treatment. This press briefing took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Related Videos

The RT1 trial of tislelizumab plus zanubrutinib for the treatment of Richter's transformation
1:30
The RT1 trial of tislelizumab plus zanubrutinib for the treatment of Richter's transformation
Daniel Zheng • 7 Dec 2025
Top updates in CLL from ASH 2025: insights into time-limited treatment from the CLL17 trial
0:53
Top updates in CLL from ASH 2025: insights into time-limited treatment from the CLL17 trial
Daniel Zheng • 7 Dec 2025
Results of the ASC2ESCALATE trial of asciminib in CML-CP with one prior TKI
2:34
Results of the ASC2ESCALATE trial of asciminib in CML-CP with one prior TKI
Daniel Zheng • 7 Dec 2025
Asciminib in patients with CML-CP who have not achieved DMR after ≥1 year of imatinib: ASC4MORE
2:15
Asciminib in patients with CML-CP who have not achieved DMR after ≥1 year of imatinib: ASC4MORE
Daniel Zheng • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals